Alvotech (ALVO) Stock Soars 8% Following Barclays’ Dramatic Rating Shift

Key Takeaways

• Barclays shifted Alvotech’s rating from Underweight to Overweight while increasing its price target from $4 to $8
• The FDA completed its inspection of Alvotech’s Iceland manufacturing site in July with a positive “Voluntary Action Indicated” outcome
• The company has three biosimilar candidates (AVT05, AVT06, AVT03) awaiting FDA approval by December 4, 2026
• Management confirmed its fiscal 2026 revenue forecast of $650 million to $700 million
• Shares surged approximately 8% on Wednesday, recording the strongest daily performance since December

Shares of Alvotech surged approximately 8% during Wednesday’s trading session following a significant analyst upgrade from Barclays. Glen Santangelo, an analyst at Barclays, reversed his stance on the biosimilar manufacturer, shifting his rating from Underweight to Overweight while simultaneously doubling his price objective from $4 to $8. The stock was changing hands near $5.42, remaining substantially below its 52-week peak of $9.25.

Alvotech, ALVO

The rally represents one of the most significant single-session advances for the stock, delivering its strongest performance since December, based on data from Dow Jones Market Data.

The rating revision comes on the heels of an important regulatory milestone. In July, the FDA officially concluded its inspection of Alvotech’s production facility located in Reykjavik, Iceland, designating it with a Voluntary Action Indicated classification. This represents the most positive inspection result the FDA can assign.

The Iceland manufacturing site had been a lingering concern among shareholders. Previous FDA inspections had identified shortcomings in manufacturing protocols and facility standards, creating obstacles for product authorizations. Importantly, the issues were limited to the facility itself, not the quality of the drug products.

Following the resolution of facility-related concerns, Alvotech resubmitted biologics license applications in June covering three biosimilar products. The FDA has established December 4, 2026, as the decision deadline for all three submissions.

Trio of Biosimilars Awaiting Approval

The three candidates pursuing regulatory clearance are biosimilars designed to address chronic inflammatory diseases, eye disorders, and skeletal health.

AVT05 serves as a biosimilar alternative to Simponi, a Johnson and Johnson therapeutic used for alleviating joint discomfort. AVT06 represents Alvotech’s biosimilar version of Eylea, jointly developed by Regeneron and Bayer for treating retinal conditions and preserving eyesight. AVT03 mimics Prolia and Xgeva, two Amgen medications for bone protection.

Additionally, the FDA has accepted a BLA submission for AVT16, a biosimilar to Entyvio, with an anticipated decision in early 2027.

Santangelo highlighted that production at full capacity restarted during the second quarter of 2026. Company leadership stood by its revenue projection of $650 million to $700 million for fiscal 2026.

Manufacturing Diversification Strategy

Beyond Iceland, Alvotech has been pursuing additional manufacturing capabilities. The company maintains a strategic collaboration with Fujifilm Biotechnologies in the United States, with enhanced production capacity scheduled to become operational in 2027.

Santangelo characterized the stock as a compelling investment opportunity, pointing to the regulatory advancements and the defined schedule for potential approvals before the end of the year.

The broader equity markets posted gains on Wednesday, with the S&P 500 advancing 0.2% and the Nasdaq climbing 0.4%, though Alvotech’s performance significantly exceeded the major indexes.

The stock continues to trade considerably beneath its 52-week high of $9.25, with three FDA determinations scheduled for December 4, 2026.